NCT01505777View on ClinicalTrials.gov

Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

PHASE2CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Irritable Bowel Syndrome Without Diarrhea
Interventions
DRUG

Probiotics (Medirac)

10/mosapride 10mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac)

15/mosapride 10mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac)

15/mosapride 15mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac)

30/mosapride 15mg three times a day, P.O. 4week

DRUG

Probiotics (Medirac) placebo/mosapride placebo

three times a day, P.O. 4week

Trial Locations (1)

Unknown

16 institutions including Gangnam Severance hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01505777 - Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea | Biotech Hunter | Biotech Hunter